Published November 04, 2012; Updated September 12, 2014
Susa Coffey, MD
Selected Reference
5. Nichols G, Mills A, Grossberg R, et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3. In: Program and abstracts of the 11th International Congress on Drug Therapy in HIV Infection; November 11-15, 2012; Glasgow, Scotland. Oral abstract 0232.